Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status.
Roscovitine induced apoptosis in isolated B-chronic lymphocytic leukemia cells of 25 patients of whom nine with relapsed and seven with fludarabine-refractory disease. It was synergistic with alemtuzumab and restored sensitivity to alemtuzumab in initially alemtuzumab-resistant samples. Observed roscovitine-induced up-regulation of CD52 surface expression may be one of the underlying mechanisms for this synergism.
Weingrill
Eva
E
Wölfler
Albert
A
Strunk
Dirk
D
Linkesch
Werner
W
Sill
Heinz
H
Liebmann
Peter M
PM
D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D015703:Antigens, CD / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D000074301:CD52 Antigen; D015331:Cohort Studies; D004357:Drug Synergism; D005260:Female; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011687:Purines / Q000008:administration & dosage; D000077546:Roscovitine; D016879:Salvage Therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D011687:Purines; D000077546:Roscovitine; D000074323:Alemtuzumab; D008942:Mitoxantrone